PMV Pharmaceuticals (PMVP) AI Stock Analysis

• Market Cap: $54.55M
• Dividend Yield: N/A
• Average Volume (3M): 287.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: N/A
• EPS Growth: 21.33%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 51,952,680
• 10 Day Avg. Volume: 128,140
• 30 Day Avg. Volume: 287,222
• PEG Ratio: -11.88
• Price to Book (P/B): -22.89
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -72.74
• Enterprise Value/Market Cap: 31.32
• Enterprise Value/Revenue: 527.98
• Enterprise Value/Gross Profit: -4.59K
• Enterprise Value/Ebitda: -5.28
• 1Y Price Target: $18.00
• Price Target Upside: 1614.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 40 Underperform
• Price Target: ―

PMV Pharmaceuticals faces significant challenges typical of a biotech firm in the pre-commercialization phase, with no revenue and high R&D costs leading to negative financials. The strong cash position offers some financial flexibility, but the lack of revenue and ongoing losses are significant concerns. Technical indicators suggest a bearish trend, and valuation metrics reflect the company's developmental stage. A path to commercialization is essential for improving financial health and investor confidence.

Positive Factors

Clinical Trials

Enrollment into the pivotal Ph2 portion of the PYNNACLE trial evaluating rezatapopt monotherapy in TP53 Y220C and KRAS WT advanced solid tumors remains on track.

Financial Performance

PMV ended 2024 with $183.3M in cash, which should fund operations to end-2026.

Regulatory Approval

More than 90% of sites are now activated across the US, Europe, and Asia-Pacific, and management expects an interim analysis and NDA filing with unchanged guidance.

Negative Factors

Clinical Data Risks

Risks include negative PC14586 clinical data, delays in moving candidates into advanced trials, and setbacks in later-stage studies.

PMV Pharmaceuticals Business Overview & Revenue Model

Company Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

How the Company Makes Money

PMV Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company focuses on advancing its pipeline of small-molecule therapies through clinical trials and aims to monetize these assets via out-licensing agreements, partnerships with larger pharmaceutical companies, or direct sales upon regulatory approval. Key revenue streams include milestone payments, royalties, and upfront fees from partnerships and collaborations, which are essential to funding ongoing research and development efforts. The company's financial success is closely tied to the successful advancement of its drug candidates through clinical trials and obtaining necessary regulatory approvals.

PMV Pharmaceuticals Financial Statement Overview

Summary

PMV Pharmaceuticals is typical of a biotech company in its pre-revenue phase, with significant R&D investments leading to high operational losses and negative cash flows. The strong cash position provides some financial flexibility, but the ongoing lack of revenue generation is a critical issue. The company needs to achieve milestones that could lead to commercialization to improve its financial health and investor confidence.

Income Statement

PMV Pharmaceuticals has consistently reported zero revenue over the years, highlighting the typical operational phase of a biotech firm focused on R&D before product commercialization. The net income is negative, with increasing losses, indicating high operational expenses relative to non-existent revenues. The absence of revenue growth and weak profit margins reflect challenges in moving towards profitability.

Balance Sheet

The company's balance sheet shows a strong equity position with significant cash reserves, providing a buffer against the continued losses. The debt-to-equity ratio is low due to minimal debt levels, which is a positive sign. However, the continuous decline in stockholders' equity and asset base over the years is a concern, indicating potential long-term sustainability issues if the trend continues without revenue generation.

Cash Flow

PMV Pharmaceuticals exhibits negative operating and free cash flows, consistent with its stage in the biotech lifecycle. While free cash flow has improved slightly, it remains negative, reflecting high operational cash usage. The lack of positive cash flow from operations indicates reliance on external financing to sustain operations, posing a risk if capital markets become less favorable.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-372.00K	0.00	-1.26M	-650.00K	-1.28M	-318.00K
EBITDA	-88.01M	-73.67M	-78.88M	-76.72M	-57.99M	-34.62M
Net Income	-60.88M	-58.71M	-68.96M	-73.32M	-57.85M	-34.44M
Balance Sheet
Total Assets	170.61M	191.29M	252.15M	270.31M	331.57M	365.53M
Cash, Cash Equivalents and Short-Term Investments	160.39M	169.45M	203.06M	241.05M	297.16M	361.42M
Total Debt	1.11M	1.19M	13.29M	13.98M	11.19M	0.00
Total Liabilities	10.50M	15.21M	26.46M	24.28M	23.01M	6.41M
Stockholders Equity	160.11M	176.08M	225.69M	246.03M	308.56M	359.12M
Cash Flow
Free Cash Flow	-53.43M	-51.94M	-56.62M	-71.74M	-47.92M	-32.89M
Operating Cash Flow	-53.36M	-51.28M	-55.66M	-63.76M	-46.57M	-32.74M
Investing Cash Flow	55.90M	53.35M	-50.55M	-1.37M	-143.58M	27.91M
Financing Cash Flow	323.00K	313.00K	35.58M	958.00K	2.02M	292.97M

PMV Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.05
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Positive. The current price of 1.05 is below the 20-day moving average (MA) of 1.07, above the 50-day MA of 0.99, and below the 200-day MA of 1.32, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 57.43 is Neutral, neither overbought nor oversold. The STOCH value of 42.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PMVP.

PMV Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	68 Neutral	$371.80M	4.76	-58.97%	―	23.81%	146.45%
Sector *	51 Neutral	$7.55B	0.39	-61.90%	2.32%	17.14%	1.55%
PDSB	50 Neutral	$55.77M	―	-119.22%	―	―	25.51%
CUE	50 Neutral	$50.67M	―	-221.66%	―	13.83%	37.66%
GUTS	45 Neutral	$80.32M	―	-196.81%	―	―	―
PMVP	40 Underperform	$54.55M	―	-32.66%	―	―	21.33%
STRO	38 Underperform	$57.43M	―	-679.15%	―	-56.88%	-57.57%